The
Australian TGA has issued a document titled “Additional safety protections
relating to COVID-19 for faecal microbiota transplant (FMT) products.”
FMT
products comprise, contain, or are derived from donated human stool and are
introduced into a recipient person for a therapeutic use. Human stool is
collected from a screened donor by defaecation. This stool is then processed
into an FMT product and provided to the recipient via enema, colonoscopy,
nasoenteric tube, or orally (e.g. capsules).
This
advice follows a recent safety alert from the US FDA that highlighted the
additional safety precautions that should be in place for COVID-19 disease
screening of potential stool donors for FMT products in order to prevent the
spread of the SARS-CoV-2 virus.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources